Extended Data Fig. 1: Differential change in immune populations between non-responding and responding biopsies during anti-PD-1 therapy. | Nature Cancer

Extended Data Fig. 1: Differential change in immune populations between non-responding and responding biopsies during anti-PD-1 therapy.

From: PAK4 inhibition improves PD-1 blockade immunotherapy

Extended Data Fig. 1: Differential change in immune populations between non-responding and responding biopsies during anti-PD-1 therapy.

Comparison (two-sided, paired T-test) of each of the immune populations and immune markers between baseline and on-treatment tumour samples for responding (n= 5) and non-responding (n= 6) biopsies. From left to right: T cell score (R P= 0.007, NR P= 0.44), Dendritic cell score (R P= 0.009, NR P= 0.08), CD8 T cell score (R P= 0.006, NR P= 0.48), CTL score (R P= 0.01, NR P= 0.43), NK cell score (R P= 0.006, NR P= 0.32), Monocyte lineage score (R P= 0.004, NR P= 0.48), IFNg (R P= 0.01, NR P= 0.47), TNF (R P= 0.01, NR P= 0.9), GZMA (R P= 0.01, NR P= 0.73), PRF1 (R P= 0.004, NR P= 0.29) and CD8A (R P= 0.004, NR P= 0.52) expression. Increase in all immune populations and markers was significant (P < 0.05) only in responding biopsies. *P <0.05, **P < 0.01; ns, not significant

Back to article page